Fungal diagnosis: How do we do it and can we do better?

Current Medical Research and Opinion

Volumn 29, Issue SUPPL4, 2013, Pages 3-11

  Perfect, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

glucan; Aspergillosis; Candidiasis; Diagnostics; Galactomannan; Invasive fungal infections; PCR assays

Indexed keywords

BETA GLUCAN; GALACTOMANNAN;

ASPERGILLOSIS; BLOOD CULTURE; CRYPTOCOCCOSIS; GENETIC POLYMORPHISM; HISTOPATHOLOGY; INVASIVE CANDIDIASIS; NONHUMAN; PATHOGENESIS; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; COLONY COUNT, MICROBIAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84876918809     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.761134     Document Type: Review

References (105)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010;36:1-53
2. Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010;18:195-204
3. Lewis JS, Boucher HW, Lubowski TJ, et al. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacotherapy 2005;25:839-46 (Pubitemid 40727136)
4. Ostrosky-Zeichner L. Invasive mycoses: diagnostic challenges. Am J Med 2012;125:S14-24
5. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9 (Pubitemid 41532664)
6. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000;31:1524-8
7. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66 (Pubitemid 32173620)
8. Slobbe L, Polinder S, Doorduijn JK, et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia- myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 2008;47:1507-12
9. Baddley JW, Patel M, Bhavnani SM, et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008;52:3022-8
10. Garey KW, Pai MP, Suda KJ, et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007;16: 919-27 (Pubitemid 47322590)
11. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006;43:25-31 (Pubitemid 43939072)
12. Garey KW, Turpin RS, Bearden DT, et al. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multiinstitutional study. Int J Antimicrob Agents 2007;29:557-62 (Pubitemid 46560362)
13. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-7 (Pubitemid 40896144)
14. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997;23:23-30 (Pubitemid 27067892)
15. Parkins MD, Sabuda DM, Elsayed S, et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007;60:613-8 (Pubitemid 47299877)
16. Tumbarello M, Posteraro B, Trecarichi EM, et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007;45:1843-50 (Pubitemid 46933916)
17. von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995;62:341-7
18. Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-40 (Pubitemid 46233255)
19. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-47 (Pubitemid 27020567)
20. Chandrasekar P. Diagnostic challenges and recent advances in the early management of invasive fungal infections. Eur J Haematol 2010;84:281-90
21. Vehreschild JJ, Ruping MJ, Steinbach A, et al. Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. Expert Opin Pharmacother 2010;11:95-113
22. Kaufman L, Standard PG, Jalbert M, et al. Immunohistologic identification of Aspergillus spp. and other hyaline fungi by using polyclonal fluorescent antibodies. J Clin Microbiol 1997;35:2206-9 (Pubitemid 27349782)
23. Bennett JE, ed. Introduction to mycoses, 7th edn. New York, NY: Churchill Livingstone, 2010
24. Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007;139:519-31 (Pubitemid 350043811)
25. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60 (Pubitemid 351265310)
26. Hadrich I, Makni F, Neji S, et al. Invasive aspergillosis: resistance to antifungal drugs. Mycopathologia 2012;174:131-41
27. Cuenca-Estrella M, Bassetti M, Lass-Florl C, et al. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011;66(Suppl 1):i15-24
28. Lanternier F, Sun HY, Ribaud P, et al. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 2012;54:1629-36
29. Liu K, Howell DN, Perfect JR, et al. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol 1998;109:45-54 (Pubitemid 28023810)
30. Berenguer J, Buck M, Witebsky F, et al. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993;17:103-9 (Pubitemid 23294544)
31. Borst A, Leverstein-Van Hall MA, Verhoef J, et al. Detection of Candida spp. in blood cultures using nucleic acid sequence-based amplification (NASBA). Diagn Microbiol Infect Dis 2001;39:155-60 (Pubitemid 32406170)
32. Creger RJ, Weeman KE, Jacobs MR, et al. Lack of utility of the lysis-centrifugation blood culture method for detection of fungemia in immunocompromised cancer patients. J Clin Microbiol 1998;36:290-3 (Pubitemid 28047482)
33. Sales Mda P. Chapter 5-Aspergillosis: from diagnosis to treatment. J Bras Pneumol 2009;35:1238-44
34. Beirao F, Araujo R. State of the art diagnostic of mold diseases: a practical guide for clinicians. Eur J Clin Microbiol Infect Dis 2012:Epub before print
35. Brodoefel H, Vogel M, Hebart H, et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome. Am J Roentgenol 2006;187:404-13 (Pubitemid 44148284)
36. Chamilos G, Marom EM, Lewis RE, et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005;41:60-6 (Pubitemid 40863745)
37. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-9 (Pubitemid 46147619)
38. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011;118: 1216-24
39. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-60
40. Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006;34:730-7
41. Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-8 (Pubitemid 24376373)
42. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001;33:177-86 (Pubitemid 32643332)
43. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007;26:271-6 (Pubitemid 46572022)
44. Zaas AK, Liao G, Chien JW, et al. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet 2008;4:e1000101
45. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008;359: 1766-77
46. Rosentul DC, Plantinga TS, Oosting M, et al. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J Infect Dis 2011;204:1138-45
47. Johnson MD, Plantinga TS, van de Vosse E, et al. Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin Infect Dis 2012;54:502-10
48. Panichakul T, Chawengkirttikul R, Chaiyaroj SC, et al. Development of a monoclonal antibody-based enzyme-linked immunosorbent assay for the diagnosis of Penicillium marneffei infection. Am J Trop Med Hyg 2002;67:443-7 (Pubitemid 35303871)
49. Rosentul DC, Plantinga TS, Scott WK, et al. The impact of caspase-12 on susceptibility to candidemia. Eur J Clin Microbiol Infect Dis 2012;31:277-80
50. Joseph Wheat L. Current diagnosis of histoplasmosis. Trends Microbiol 2003;11:488-94
51. Durkin M, Witt J, Lemonte A, et al. Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol 2004;42:4873-5 (Pubitemid 39362430)
52. Weiner MH. Antigenemia detected in human coccidioidomycosis. J Clin Microbiol 1983;18:136-42 (Pubitemid 13056823)
53. da Silva SH, Grosso Dde M, Lopes JD, et al. Detection of Paracoccidioides brasiliensis gp70 circulating antigen and follow-up of patients undergoing antimycotic therapy. J Clin Microbiol 2004;42:4480-6 (Pubitemid 39362359)
54. Gade W, Hinnefeld SW, Babcock LS, et al. Comparison of the PREMIER cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens. J Clin Microbiol 1991;29: 1616-19
55. Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIVassociated cryptococcal meningitis. Clin Infect Dis 2011;53:1019-23
56. Tanner DC, Weinstein MP, Fedorciw B, et al. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol 1994;32:1680-4 (Pubitemid 24189556)
57. Temstet A, Roux P, Poirot JL, et al. Evaluation of a monoclonal antibody-based latex agglutination test for diagnosis of cryptococcosis: comparison with two tests using polyclonal antibodies. J Clin Microbiol 1992;30:2544-50
58. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009;23:525-30
59. Jarvis JN, Meintjes G, Harrison TS. Outcomes of cryptococcal meningitis in antiretroviral naive and experienced patients in South Africa. J Infect 2010;60:496-8
60. Jarvis JN, Meintjes G, Wood R, et al. Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. AIDS 2010;24:1233-5
61. Kendi C, Penner J, Otieno B, et al. Routine cryptococcal screening and treatment in Kenya: outcomes after six months of follow-up. Sixth International AIDS Society conference. 2011; abstract TUPE150
62. Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4\+cell count5or100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010;51:448-55
63. Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 2012;59:e85-91
64. Yoshida M. Beta-D-Glucan Testing. In: Pasqualotto AC, ed. Aspergillosis: From diagnosis to prevention. New York, NY: Springer\+Business media B.V.; 2010: 125-34
65. Mohr J, Johnson M, Cooper T, et al. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008;28:614-45 (Pubitemid 351620030)
66. Obayashi T, Yoshida M, Mori T, et al. Plasma (1-43)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995;345:17-20
67. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199-205 (Pubitemid 38971490)
68. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1-43) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41:654-9 (Pubitemid 41170353)
69. Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008;46:878-85 (Pubitemid 351417190)
70. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. Beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011;52:750-70
71. Lamoth F, Cruciani M, Mengoli C, et al. beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012;54:633-43
72. Hanson KE, Pfeiffer CD, Lease ED, et al. Beta-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One 2012;7:e42282
73. Takesue Y, Kakehashi M, Ohge H, et al. Combined assessment of beta-Dglucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 2004;28:625-30 (Pubitemid 38802803)
74. Sims CR, Jaijakul S, Mohr J, et al. Correlation of clinical outcomes with betaglucan levels in patients with invasive candidiasis. J Clin Microbiol 2012;50:2104-6
75. McMullan R, Metwally L, Coyle PV, et al. A prospective clinical trial of a realtime polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 2008;46:890-6 (Pubitemid 351417192)
76. Wilson DA, Joyce MJ, Hall LS, et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol 2005;43:2909-12 (Pubitemid 40827971)
77. Pfeiffer CD, Samsa GP, Schell WA, et al. Quantitation of Candida CFU in initial positive blood cultures. J Clin Microbiol 2011;49:2879-83
78. Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012;54:1240-8
79. Zaas AK, Aziz H, Lucas J, et al. Blood gene expression signatures predict invasive candidiasis. Sci Transl Med 2010;2:21ra17
80. Schell WA, Benton JL, Smith PB, et al. Evaluation of a digital microfluidic realtime PCR platform to detect DNA of Candida albicans in blood. Eur J Clin Microbiol Infect Dis 2012;31:2237-45
81. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:1417-27
82. Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003;121:448-57 (Pubitemid 36628336)
83. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008;177:27-34
84. Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004;42:5517-22 (Pubitemid 39664330)
85. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51
86. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242-50 (Pubitemid 41534660)
87. Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2009;115:355-62
88. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008;46:1412-22 (Pubitemid 351589942)
89. Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007;110:830-4 (Pubitemid 47257661)
90. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications. Cancer 2007;110:112-20 (Pubitemid 46986424)
91. Kami M, Fukui T, Ogawa S, et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001;33:1504-12 (Pubitemid 34246144)
92. Perfect JR. The impact of the host on fungal infections. Am J Med 2012;125:S39-51
93. Avni T, Levy I, Sprecher H et al. Diagnostic accuracy of PCR alone and compared to galactomannan in bronchoalveolar lavage for the diagnosis of invasive pulmonary aspergillosis: systematic review. J Clin Microbiol 2012:50:3652-8
94. Bretagne S. Primary diagnostic approaches of invasive aspergillosis-molecular testing. Med Mycol 2011;49(Suppl 1):S48-53
95. Mengoli C, Cruciani M, Barnes RA, et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:89-96
96. European Aspergillus PCR Initiative (EAPCRI) working group. Available at: http://www.eapcri.eu/[Last accessed 18 September 2012]
97. White Jr AC, Atmar RL, Wilson J, et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230-9 (Pubitemid 127775484)
98. White PL, Bretagne S, Klingspor L, et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010;48:1231-40
99. White PL, Mengoli C, Bretagne S, et al. Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol 2011;49:3842-8
100. Lass-Flö rl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007;45:e101-4 (Pubitemid 47580399)
101. Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007;44:1078-83 (Pubitemid 46580276)
102. Tuon FF. A systematic literature review on the diagnosis of invasive aspergillosis using polymerase chain reaction (PCR) from bronchoalveolar lavage clinical samples. Rev Iberoam Micol 2007;24:89-94 (Pubitemid 47025141)
103. Sun W, Wang K, Gao W, et al. Evaluation of PCR on bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis: a bivariate metaanalysis and systematic review. PLoS One 2011;6:e28467
104. Lass-Florl C, Gunsilius E, Gastl G, et al. Clinical evaluation of Aspergillus-PCR for detection of invasive aspergillosis in immunosuppressed patients. Mycoses 2005;48(Suppl 1):12-17 (Pubitemid 40592861)
105. Reinwald M, Hummel M, Kovalevskaya E, et al. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother 2012;67:2260-7